Drug permeation through biomembranes: Cyclodextrins and the unstirred water layer

Pharmazie

Volumn 67, Issue 5, 2012, Pages 363-370

  Loftsson, Thorsteinn ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANDROGRAPHOLIDE; ANDROSTENEDIOL; ARTEMISININ; ATENOLOL; CANNABINOL; CINNARIZINE; CYCLODEXTRIN; CYCLOSPORIN A; DANAZOL; DIPHENHYDRAMINE; DORZOLAMIDE; DRONABINOL; ESTRADIOL; FLUFENAMIC ACID; FLURBIPROFEN; GLIBENCLAMIDE; INDOMETACIN; PERPHENAZINE; PIROXICAM; PRASTERONE; ROFECOXIB; WATER;

AQUEOUS HUMOR; AQUEOUS SOLUTION; COMPLEX FORMATION; DIFFUSION COEFFICIENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIPID BILAYER; LIPOPHILICITY; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; REVIEW; VISCOSITY;

ADMINISTRATION, BUCCAL; ADMINISTRATION, OPHTHALMIC; ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; CHEMISTRY, PHYSICAL; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; MEMBRANES; MODELS, MOLECULAR; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; WATER;

EID: 84862322838     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1698     Document Type: Review

References (97)

1. Antonenko YN, Pohl P (1995) Steady-state nonmonotonic concentration profiles in the unstirred layers of bilayer membranes. Biochim Biophys Acta 1235: 57-61.
2. Artiss JD, Brogan K, Brucal M, Moghaddam M, Jen K-LC (2006) The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. Metab Clin Exp 55: 195-202.
3. Avdeef A, Nielsen PE, Tsinman O (2004) PAMPA - a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur J Pharm Sci 22: 365-374.
4. Badawy SIF, Ghorab MM, Adeyeye CM (1996a) Bioavailability of danazol-hydroxypropyl-β-cyclodextrin complex by different routes of administration. Int J Pharm 145: 137-143.
5. Badawy SIF, Ghorab MM, Adeyeye CM (1996b) Characterization and bioavailability of danazol-hydroxypropyl-β-cyclodextrin coprecipitates. Int J Pharm 128: 45-54.
6. Bansil R, Turner BS (2006) Mucin structure, aggregation, physiological functions and biomedical applications. Curr Opin Colloid Interface Sci 11: 164-170.
7. Behrens I, Stenberg P, Artursson P, Kissel T (2001) Transport of lipophilic drug molecules in new mucus-secreting cell culture model based on HT29-MTX cells. Pharm Res 18: 1138-1145.
8. Bonn M, Bakker HJ, Ghosh A, Yamamoto S, Sovago M, Campen RK (2010) Structural inhomogeneity of interfacialwater at lipid monolayers revealed by surface-specific vibrational pump-probe spectroscopy. J Am Chem Soc 132: 14971-14978.
9. Branca C, Magazù S, Maisano G, Migliardo P, Migliardo F, Romeo G (2002) Hydration parameters of aqueous solutions of poly(ethylene glycol)s by viscosity data. Phys Scrip 66: 175-179.
10. Brewster ME, Loftsson T (2007) Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59: 645-666.
11. Brewster ME, Noppe M, Peeters J, Loftsson T (2007) Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int J Pharm 342: 250-253.
12. Brouwers J, Brewster ME, Augustijns P (2009) Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 98: 2549-2572.
13. Brown GA, Martin ER, Roberts BS, Vukovich MD, King DS (2002) Acute hormonal response to sublingual androstenediol in young men. J Appl Physiol 92: 142-146.
14. Cabane B, Vuilleumier R (2005) The physics of liquid water. CR Geoscience 337: 159-171.
15. Carrier RL, Miller LA, Ahmed I (2007) The ultility of cyclodextrins for enhancing oral bioavailability. J Control Release 123: 78-99.
16. Challa R, Ahuja A, Ali J, Khar RK (2005) Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 6(2), E329-357.
17. Chaplin M (2011a) The water molecule, liquid water, hydrogen bonds and water networks. In: Bihan DL, Fukuyama H (Eds.) Water: The forgotten biological molecule, Pan Stanford Publishing Pte. Ltd., Singapore, p. 3-19.
18. Chaplin M (2011b) Water structure and science (www.lsbu.ac.uk/water).
19. Chavanpatil M, Dawre FD, Shakleya DS, Vavia PR (2002) Enhancement of oral bioavailability of rofecoxib using β-cyclodextrin. J Incl Phenom Macroc Chem 44: 145-149.
20. Corvi Mora P, Cirri M, Allolio B, Carli F, Mura P (2003) Enhancement of dehydroepianhydrosterone solubility and bioavailability by ternary complexation with a-cyclodextrin and glycine. J Pharm Sci 92: 2177-2184.
21. Cukierman S (2006) Et tu, Grotthuss! and other unfinished stories. Biochim Biophys Acta Bioenergetics 1757: 876-885.
22. Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL (2010) The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: Mechanistic modeling and application to progesterone. J Pharm Sci 99: 2739-2749.
23. Dalvit C, Caronni D, Mongelli N, Veronesi M, Vulpetti A (2006) NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. Curr Drug Discov Technol 3: 115-124.
24. Deroubaix X, Stockis A, Allemon aM, Lebacq E, Acerbi D, Ventura P (1995) Oral bioavailability of CHF1194, an inclusion complex of piroxicam and b-cyclodextrin, in healthy-subjects under single-dose and steady-state conditions. Eur J Clin Pharmacol 47: 531-536.
25. Disalvo EA, Lairion F, Martini F, Almaleck H, Diaz S, Gordillo G (2004) Water in biological membranes at interfaces: does it play a functional role? J Argent Chem Soc 92: 1-22.
26. Eaves JD, Loparo JJ, Fecko CJ, Roberts ST, Tokmakoff A, Geissler PL (2005) Hydrogen bonds in liquid water are broken only fleetingly. Proc Natl Acad Sci USA 102: 13019-13022.
27. Elkheshen SA, Ahmed SM, Al-Quadeib BT (2002) Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin - 2nd communication: in vitro and in vivo drug availability. Pharm Ind 64: 708-715.
28. Flynn GL, Carpender OS, Yalkowsky SH (1972) Total mathematical resolution of diffusion layer control of barrier flux. J Pharm Sci 61: 312-314.
29. Flynn GL, Yalkowsky SH (1972) Correlation and prediction of mass transport across membranes I: influence of alkyl chain length on flux-determining properties of barrier and diffusant. J Pharm Sci 61: 838-852.
30. Fridriksdóttir H, Loftsson T, Gudmundsson JA, Bjarnason GJ, Kjeld M, Thorsteinsson T (1996) Design and in vivo testing of 17β-estradiol- HPβCD sublingual tablets. Pharmazie 51: 39-42.
31. Giangiacomo R (2006) Study of water-sugar interactions at increasing sugar concentration by NIR spectroscopy. Food Chem Tox 96: 371-379.
32. Griffith JH, Scheraga HA (2004) Statistical thermodynamics of aqueous solutions. I. Water structure, solutions with non-polar solutes, and hydrophobic interactions. J Mol Str 682: 97-113.
33. Hasted JB (1972) Liquid water: dielectric properties. In: Franks F (Ed.) Water, a comprehensive treatise, Plenum Press, New York, p. 255-309.
34. Head-Gordon T, JohnsonME(2006) Tetrahedral structure or chains of liquid water. Proc Natl Acad Sci USA 103: 7973-7977.
35. Higuchi T (1960) Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 11: 85-97.
36. Higuchi T, Connors KA (1965) Phase-solubility techniques. Adv Anal Chem Instrum 4: 117-212.
37. Hoon TJ, Dawood MY, Khan-Dawood FS, Ramos J, Batenhorst RL (1993) Bioequivalence of 17β-estradiol hydroxypropyl-β-cyclodextrin complex in postmenopausal women. J Clin Pharmacol 33: 1116-1121.
38. Jain a C, Aungst BJ, Adeyeye MC (2002) Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 β-cyclodextrin (SBE 7) complexes. J Pharm Sci 91: 1659-1668.
39. Jambhekar S, Casella R, Maher T (2004) The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, hydroxyethyl-β-cyclodextrin, and hydroxypropyl-β-cyclodextrin complexes. Int J Pharm 270: 149-166.
40. Jansook P, Stefánsson E, Thorsteinsdóttir M, Sigurdsson BB, Kristjánsdóttir SS, Bas J F, Sigurdsson HH, Loftsson T (2010) Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm 76: 208-214.
41. Järvinen T, Järvinen K, Schwarting N, Stella VJ (1995) β-Cyclodextrin derivatives, SBE4-β-CD and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J Pharm Sci 84: 295-299.
42. Jayachandra Babu R, Pandit JK (1995) Enhancement of dissolution rate and hypoglycemic activity of glibenclamide with β-cyclodextrin. S.T.P. Pharma Sci 5: 196-201.
43. Jug M, Bećirević-Laćan M, Bengez S (2009) Novel cyclodextrin-based film formulation intended for buccal delivery of atenolol. Drug Devel Ind Pharm 35: 796-807.
44. Karlsson JP, Artursson P (1991) A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelia (Caco-2) cells grown in permeable filter chambers. Int J Pharm 71: 55-64.
45. Khanvilkar K, Donovan MD, Flanagan DR (2001) Drug transfer through mucus. Adv Drug Deliv Rev 48: 173-193.
46. Kimura E, Bersani-Amado CA, Sudo LS, Santos SRJ, Oga S (1997) Pharmacokinetic profile of piroxicam β-cyclodextrin, in rat plasma and lymph. Gen Pharmac 28: 695-698.
47. Lai SK, Wang Y-Y, Hanes J (2009a) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61: 158-171.
48. Lai SK, Wang Y-Y, Wirtz D, Hanes J (2009b) Micro- and macrorheology of mucus. Adv Drug Deliv Rev 61: 86-100.
49. Le Corre P, Dollo G, Chevanne F, Le Verge R (1998) Influence of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin on diphenhydramine intestinal absorption in a rat in situ model. Int J Pharm 169: 221-228.
50. Liversidge GG, Cundy KC (1995) Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs. 1. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125: 91-97.
51. Loftsson T (2002) Cyclodextrins and the biopharmaceutics classification system of drugs. J Incl Phenom Macroc Chem 44: 63-67.
52. Loftsson T (2010) Aqueous solubility and true solutions. Pharmazie 65: 404-407.
53. Loftsson T, Brewster ME (2008) Physicochemical properties of water and its effect on drug delivery. A commentary. Int J Pharm 354: 248-254.
54. Loftsson T, Brewster ME (2010) Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 62: 1607-1621.
55. Loftsson T, Brewster ME (2011) Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol 63: 1119-1135.
56. Loftsson T, Brewster ME, Másson M (2004) Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2: 261-275.
57. Loftsson T, Guomundsson JA, Árnadóttir RO, Frioriksdóttir H (2003) Sublingual delivery of 17β -estradiol from cyclodextrin containing tablets. Pharmazie 58: 358-359.
58. Loftsson T, Hreinsdóttir D, Másson M (2005) Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 302: 18-28.
59. Loftsson T, Hreinsdóttir D, Stefánsson E (2007a) Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol 59: 629-635.
60. Loftsson T, Järvinen T (1999) Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 36: 59-79.
61. Loftsson T, Másson M, Sigurjónsdóttir JF (1999) Methods to enhance the complexation efficiency of cyclodextrins. S.T.P. Pharma Sci 9: 237-242.
62. Loftsson T, Sigurosson HH, Konráosdóttir F, Gísladóttir S, Jansook P, Stefánsson E (2008) Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 63: 171-179.
63. Loftsson T, Stefánsson E (2007) Cyclodextrins in ocular drug delivery. J Drug Del Sci Tech 17: 3-9.
64. Loftsson T, Vogensen SB, Brewster ME, Konráosdóttir F (2007b) Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 96: 2532-2546.
65. Mannila J, Jarvinen K, Holappa J, Matilainen L, Auriola S, Jarho P (2010) Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. Int J Pharm 381: 19-24.
66. Mannila J, JarvinenT, Jarvinen K, Jarho P (2007) Precipitation complexation method produces cannabidiol/β-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. J Pharm Sci. 96: 312-319.
67. Mannila J, Jarvinen T, Jarvinen K, Tervonen J, Jarho P (2006) Sublingual administration of Δ9-tetrahydrocannabinol/β-cyclodextrin complex increases the bioavailability of Δ9-tetrahydrocannabinol in rabbits. Life Sci 78: 1911-1914.
68. Matsuda H, Arima H (1999) Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev 36: 81-99.
69. Mcbrierty VJ, Martin SJ, Karasz FE (1999) Understanding hydrated polymers: the perspective of NMR. J Mol Liq 80: 179-205.
70. Mcewen J (2000) Clinical pharmacology of piroxicam-β-cyclodextrin. Implications for innovative patient care. Clin Drug Invest 19 (Suppl. 2): 27-31.
71. Michot LJ, Villiéras F, François M, Bihannic I, Pelltier M, Cases JM (2002) Water organisation at the solid-aqueous solution interface.CRGeoscience 334: 611-631.
72. Mura P, Corti G, Cirri M, Maestrelli F, Mennini N, Bragagni M (2010) Development of mucoadhesive films for buccal administration of flufenamic acid: effect of cyclodextrin complexation. J Pharm Sci 99: 3019-3029.
73. Näslund L-Å, Cavalleri M, Ogasawara H, Nilsson A, Pettersson LGM, Wernet P, Edwards D C, Sandström M, Myneni S (2003) Direct evidence of orbital mixing between solvated transition-metal ions: an oxygen 1 s XAS and DFT study of aqueous systems. J Phys Chem A 107: 6869-6876.
74. O'Neil MJ, Smith A, Heckelman PE, Obenchain JR, Gallipeau JR, D'arecca MA(Eds.) (2001) The Merck Index, an encyclopedia of chemicals, drugs, and biologicals. Merck & Co., Whitehouse Station.
75. Otero-Espinar FJ, Luzardo-Alvarez A, Blanco-Mendez J (2010) Cyclodextrins: more than pharmaceutical excipients. Mini-Rev Med Chem 10: 715-725.
76. Rachid O, Rawas-Qalaji M, Simons FER, Simons KJ (2011) Dissolution testing of sublingual tablets: a novel in vitro method.AAPSPharmSciTech 12: 544-552.
77. Ren K, Zhang Z, Li Y, Liu J, Zhao D, Zhao Y, Gong T (2009) Physicochemical characteristics and oral bioavailability of andrographolide complexed with hydroxypropyl-β-cyclodextrin. Pharmazie 64: 515-520.
78. Savolainen J, Järvinen K, Taipale H, Jarho P, Loftsson T, Järvinen T (1998) Coadministration of a water-soluble polymer increases the usefulness of cyclodextrins in solid dosage forms. Pharm Res 15: 1696-1701.
79. Schmid R (2001) Recent advances in the description of the structure of water, the hydrophobic effect, and the like-dissolves-like rule. Chem Month 132: 1295-1326.
80. Sigurdsson HH, Stefánsson E, Gudmundsdóttir E, Eysteinsson T, Thorsteinsdóttir M, Loftsson T (2005) Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J Control Release 102: 255-262.
81. Stella VJ, He Q (2008) Cyclodextrins. Tox Pathol 36: 30-42.
82. Stella VJ, Rao VM, Zannou EA, Zia V (1999) Mechanism of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 36: 3-16.
83. Sugano K (2010) Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect. Int J Pharm 387: 103-109.
84. Tanito M, Hara K, Takai Y, Matsuoka Y, Nishimura N, Jansook P, Loftsson T, Stefánsson E (2011) Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci 52: 7944-7948.
85. Tokumura T, Muraoka A, Machida Y (2009) Improvement of oral bioavailability of flurbiprofen from flurbiprofen/β-cyclodextrin inclusion complex by action of cinnarizine. Eur J Pharm Biopharm 73: 202-204.
86. Tokumura T, Nanba M, Tsushima Y, Tatsuishi K, Kayano M, Machida Y, Nagai T (1986) Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. J Pharm Sci 75: 391-394.
87. Tokumura T, Tsushima Y, Kayano M, Machida Y, Nagai T (1985) Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. J Pharm Sci 74: 496-497.
88. Turunen E, Mannila J, Laitinen R, Riikonen J, Lehto V-P, Järvinen T, Ketolainen J, Järvinen K, Jarho P (2011) Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits. J Pharm Pharmacol 63: 19-25.
89. Uekama K, Hirayama F, Irie T (1998) Cyclodextrin drug carrier systems. Chem Rev 98: 2045-2076.
90. Uekama K, Udo K, Irie T, Yoshida A, Otagiri M, Seo H, Tsuruoka M (1987) Improvement of dissolution and absorption characteristics of indomethacin by water-soluble a-cyclodextrin-epichlorohydrin polymer. Acta Pharm Suec 24: 27-36.
91. Vyas A, Saraf S, Saraf S (2008) Cyclodextrin based novel drug delivery systems. J Incl Phenom Macrocycl Chem 62: 23-42.
92. Wakisaka A, Matsuura K (2006) Microheterogeneity of ethanol-water binary mixtures observed at the cluster level. J Mol Liq 129: 25-32.
93. Wernet P, Nordlund D, Bergmann U, Cavalleri M, Odelius M, Ogasawara H, Näslund L Å, Hirsch T K, Ojamäe L, Glatzel P, Pettersson LGM, Nilsson A (2004) The structure of the first coordination shell in liquid water. Science 304: 995-999.
94. Wong JW, Yuen KH (2001) Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrins. Int J Pharm 227: 177-185.
95. Woodcock BG, Acerbi D, Merz PG, Rietbrock S, RietbrockN(1993) Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur J Rheumat Inflamm 12: 12-28.
96. Yaminsky VV, Vogler EA (2001) Hydrophobic hydration. Curr Opin Colloid Interface Sci 6: 342-349.
97. Youdim KA, Avdeef A, Abbott NJ (2003) In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov Today 8: 997-1003.